PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism

Sana       Shafi; Pawan       Gupta; Gopal    Lal   Khatik; Jeena       Gupta
doi:10.2174/1389450120666190527115538
Abstract

Intense research interests have been observed in establishing PPAR gamma as a therapeutic target for diabetes. However, PPARγ is also emerging as an important therapeutic target for varied disease states other than type 2 diabetes like neurodegenerative disorders, cancer, spinal cord injury, asthma, and cardiovascular problems. Furthermore, glitazones, the synthetic thiazolidinediones, also known as insulin sensitizers, are the largely studied PPARγ agonists and the only ones approved for the treatment of type 2 diabetes. However, they are loaded with side effects like fluid retention, obesity, hepatic failure, bone fractures, and cardiac failure; which restrict their clinical application. Medicinal plants used traditionally are the sources of bioactive compounds to be used for the development of successful drugs and many structurally diverse natural molecules are already established as PPARγ agonists. These natural partial agonists when compared to full agonist synthetic thiazolidinediones led to weaker PPARγ activation with lesser side effects but are not thoroughly investigated. Their thorough characterization and elucidation of mechanistic activity might prove beneficial for counteracting diseases by modulating PPARγ activity through dietary changes. We aim to review the therapeutic significance of PPARγ for ailments other than diabetes and highlight natural molecules with potential PPARγ agonistic activity.
Keywords: PPARγ agonists, natural products, therapeutic agents, metabolic syndrome, cancer.
« Previous Next »
Graphical Abstract

[1] 
Laudet V, Hänni C, Coll J, Catzeflis F, Stéhelin D. Evolution of the nuclear receptor gene superfamily. EMBO J  1992; 11(3): 1003-13.
[http://dx.doi.org/10.1002/j.1460-2075.1992.tb05139.x] [PMID:  1312460] 
[2] 
Michalik L, Auwerx J, Berger JP, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev  2006; 58(4): 726-41.
[http://dx.doi.org/10.1124/pr.58.4.5] [PMID:  17132851] 
[3] 
Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature  1990; 347(6294): 645-50.
[http://dx.doi.org/10.1038/347645a0] [PMID:  2129546] 
[4] 
Berger J, Leibowitz MD, Doebber TW, et al. Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARdelta ligands produce distinct biological effects. J Biol Chem  1999; 274(10): 6718-25.
[http://dx.doi.org/10.1074/jbc.274.10.6718] [PMID:  10037770] 
[5] 
Dussault I, Forman BM. Prostaglandins and fatty acids regulate transcriptional signaling via the peroxisome proliferator activated receptor nuclear receptors. Prostaglandins Other Lipid Mediat  2000; 62(1): 1-13.
[http://dx.doi.org/10.1016/S0090-6980(00)00071-X] [PMID:  10936411] 
[6] 
Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med  2004; 10(4): 355-61.
[http://dx.doi.org/10.1038/nm1025] [PMID:  15057233] 
[7] 
Gearing KL, Göttlicher M, Teboul M, Widmark E, Gustafsson JA. Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci USA  1993; 90(4): 1440-4.
[http://dx.doi.org/10.1073/pnas.90.4.1440] [PMID:  8381967] 
[8] 
Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol  1996; 12(1): 335-63.
[http://dx.doi.org/10.1146/annurev.cellbio.12.1.335] [PMID:  8970730] 
[9] 
Yu S, Reddy JK. Transcription coactivators for peroxisome proliferator-activated receptors. Biochim Biophys Acta  2007; 1771(8): 936-51.
[http://dx.doi.org/10.1016/j.bbalip.2007.01.008] [PMID:  17306620] 
[10] 
Feige JN, Auwerx J. Transcriptional coregulators in the control of energy homeostasis. Trends Cell Biol  2007; 17(6): 292-301.
[http://dx.doi.org/10.1016/j.tcb.2007.04.001] [PMID:  17475497] 
[11] 
Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes  1997; 46(8): 1319-27.
[http://dx.doi.org/10.2337/diab.46.8.1319] [PMID:  9231657] 
[12] 
Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis  2009; 205(1): 1-8.
[http://dx.doi.org/10.1016/j.atherosclerosis.2009.03.008] [PMID:  19386311] 
[13] 
Barish GD, Narkar VA, Evans RM. PPAR δ: a dagger in the heart of the metabolic syndrome. J Clin Invest  2006; 116(3): 590-7.
[http://dx.doi.org/10.1172/JCI27955] [PMID:  16511591] 
[14] 
Seedorf U, Aberle J. Emerging roles of PPARdelta in metabolism. Biochim Biophys Acta  2007; 1771(9): 1125-31.
[http://dx.doi.org/10.1016/j.bbalip.2007.04.017] [PMID:  17588807] 
[15] 
Vidal-Puig AJ, Considine RV, Jimenez-Liñan M, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest  1997; 99(10): 2416-22.
[http://dx.doi.org/10.1172/JCI119424] [PMID:  9153284] 
[16] 
Medina-Gomez G, Gray SL, Yetukuri L, et al. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet  2007; 3(4)e64
[http://dx.doi.org/10.1371/journal.pgen.0030064] [PMID:  17465682] 
[17] 
Zhu Y, Qi C, Korenberg JR, et al. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci USA  1995; 92(17): 7921-5.
[http://dx.doi.org/10.1073/pnas.92.17.7921] [PMID:  7644514] 
[18] 
Fajas L, Auboeuf D, Raspé E, et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem  1997; 272(30): 18779-89.
[http://dx.doi.org/10.1074/jbc.272.30.18779] [PMID:  9228052] 
[19] 
Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig AJ, Flier JS. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor γ (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. J Biol Chem  1997; 272(32): 20230-5.
[http://dx.doi.org/10.1074/jbc.272.32.20230] [PMID:  9242701] 
[20] 
Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem  2008; 77: 289-312.
[http://dx.doi.org/10.1146/annurev.biochem.77.061307.091829] [PMID:  18518822] 
[21] 
Na HK, Surh YJ. Peroxisome proliferator-activated receptor γ (PPARgamma) ligands as bifunctional regulators of cell proliferation. Biochem Pharmacol  2003; 66(8): 1381-91.
[http://dx.doi.org/10.1016/S0006-2952(03)00488-X] [PMID:  14555212] 
[22] 
Heikkinen S, Auwerx J, Argmann CA. PPARgamma in human and mouse physiology. Biochim Biophys Acta  2007; 1771(8): 999-1013.
[http://dx.doi.org/10.1016/j.bbalip.2007.03.006] [PMID:  17475546] 
[23] 
Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia  1999; 42(9): 1033-49.
[http://dx.doi.org/10.1007/s001250051268] [PMID:  10447513] 
[24] 
Christodoulides C, Vidal-Puig A. PPARs and adipocyte function. Mol Cell Endocrinol  2010; 318(1-2): 61-8.
[http://dx.doi.org/10.1016/j.mce.2009.09.014] [PMID:  19772894] 
[25] 
Picard F, Auwerx J. PPAR(γ) and glucose homeostasis. Annu Rev Nutr  2002; 22(1): 167-97.
[http://dx.doi.org/10.1146/annurev.nutr.22.010402.102808] [PMID:  12055342] 
[26] 
Ahmadian M, Suh JM, Hah N, et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med  2013; 19(5): 557-66.
[http://dx.doi.org/10.1038/nm.3159] [PMID:  23652116] 
[27] 
Barak Y, Nelson MC, Ong ES, et al. PPAR γ is required for placental, cardiac, and adipose tissue development. Mol Cell  1999; 4(4): 585-95.
[http://dx.doi.org/10.1016/S1097-2765(00)80209-9] [PMID:  10549290] 
[28] 
Szatmari I, Rajnavolgyi E, Nagy L. PPARgamma, a lipid-activated transcription factor as a regulator of dendritic cell function. Ann N Y Acad Sci  2006; 1088: 207-18.
[http://dx.doi.org/10.1196/annals.1366.013] [PMID:  17192567] 
[29] 
Széles L, Töröcsik D, Nagy L. PPARgamma in immunity and inflammation: cell types and diseases. Biochim Biophys Acta  2007; 1771(8): 1014-30.
[http://dx.doi.org/10.1016/j.bbalip.2007.02.005] [PMID:  17418635] 
[30] 
Huang W, Glass CK. Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance. Arterioscler Thromb Vasc Biol  2010; 30(8): 1542-9.
[http://dx.doi.org/10.1161/ATVBAHA.109.191189] [PMID:  20631355] 
[31] 
Glass CK, Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol  2010; 10(5): 365-76.
[http://dx.doi.org/10.1038/nri2748] [PMID:  20414208] 
[32] 
Han S, Roman J. Peroxisome proliferator-activated receptor γ: a novel target for cancer therapeutics? Anticancer Drugs  2007; 18(3): 237-44.
[http://dx.doi.org/10.1097/CAD.0b013e328011e67d] [PMID:  17264754] 
[33] 
Reka AK, Kurapati H, Narala VR, et al. Peroxisome proliferator-activated receptor-γ activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther  2010; 9(12): 3221-32.
[http://dx.doi.org/10.1158/1535-7163.MCT-10-0570] [PMID:  21159608] 
[34] 
Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci USA  1997; 94(9): 4318-23.
[http://dx.doi.org/10.1073/pnas.94.9.4318] [PMID:  9113987] 
[35] 
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem  1995; 270(22): 12953-6.
[http://dx.doi.org/10.1074/jbc.270.22.12953] [PMID:  7768881] 
[36] 
Cho N, Momose Y. Peroxisome proliferator-activated receptor γ agonists as insulin sensitizers: from the discovery to recent progress. Curr Top Med Chem  2008; 8(17): 1483-507.
[http://dx.doi.org/10.2174/156802608786413474] [PMID:  19075761] 
[37] 
Choi JH, Banks AS, Estall JL, et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature  2010; 466(7305): 451-6.
[http://dx.doi.org/10.1038/nature09291] [PMID:  20651683] 
[38] 
Wang L, Waltenberger B, Pferschy-Wenzig EM, et al. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review. Biochem Pharmacol  2014; 92(1): 73-89.
[http://dx.doi.org/10.1016/j.bcp.2014.07.018] [PMID:  25083916] 
[39] 
Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncol  2004; 5(7): 419-29.
[http://dx.doi.org/10.1016/S1470-2045(04)01509-8] [PMID:  15231248] 
[40] 
Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res  2011; 2(4): 236-40.
[http://dx.doi.org/10.4103/2231-4040.90879] [PMID:  22247890] 
[41] 
Arck P, Toth B, Pestka A, Jeschke U. Nuclear receptors of the peroxisome proliferator-activated receptor (PPAR) family in gestational diabetes: from animal models to clinical trials. Biol Reprod  2010; 83(2): 168-76.
[http://dx.doi.org/10.1095/biolreprod.110.083550] [PMID:  20427759] 
[42] 
Elasy TA, Griffin M. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association: response to Nesto. Diabetes Care  2004; 27(8): 2096.
[http://dx.doi.org/10.2337/diacare.27.8.2096] [PMID:  15277462] 
[43] 
Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med  2006; 355(23): 2427-43.
[http://dx.doi.org/10.1056/NEJMoa066224] [PMID:  17145742] 
[44] 
Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci USA  1997; 94(9): 4312-7.
[http://dx.doi.org/10.1073/pnas.94.9.4312] [PMID:  9113986] 
[45] 
Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med  2000; 132(2): 121-4.
[http://dx.doi.org/10.7326/0003-4819-132-2-200001180-00006] [PMID:  10644273] 
[46] 
Ku YH, Cho BJ, Kim MJ, et al. Rosiglitazone increases endothelial cell migration and vascular permeability through Akt phosphorylation. BMC Pharmacol Toxicol  2017; 18(1): 62.
[http://dx.doi.org/10.1186/s40360-017-0169-y] [PMID:  28854981] 
[47] 
Neschen S, Morino K, Dong J, et al. n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner. Diabetes  2007; 56(4): 1034-41.
[http://dx.doi.org/10.2337/db06-1206] [PMID:  17251275] 
[48] 
Krey G, Braissant O, L’Horset F, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol  1997; 11(6): 779-91.
[http://dx.doi.org/10.1210/mend.11.6.0007] [PMID:  9171241] 
[49] 
Margeli A, Kouraklis G, Theocharis S. Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis. Angiogenesis  2003; 6(3): 165-9.
[http://dx.doi.org/10.1023/B:AGEN.0000021377.13669.c0] [PMID:  15041792] 
[50] 
Umesono K, Murakami KK, Thompson CC, Evans RM. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell  1991; 65(7): 1255-66.
[http://dx.doi.org/10.1016/0092-8674(91)90020-Y] [PMID:  1648450] 
[51] 
Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev  1999; 20(5): 649-88.
[PMID:  10529898] 
[52] 
Greene ME, Blumberg B, McBride OW, et al. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr  1995; 4(4-5): 281-99.
[PMID:  7787419] 
[53] 
Beamer BA, Negri C, Yen CJ, et al. Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene. Biochem Biophys Res Commun  1997; 233(3): 756-9.
[http://dx.doi.org/10.1006/bbrc.1997.6540] [PMID:  9168928] 
[54] 
Elbrecht A, Chen Y, Cullinan CA, et al. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ 1 and γ 2. Biochem Biophys Res Commun  1996; 224(2): 431-7.
[http://dx.doi.org/10.1006/bbrc.1996.1044] [PMID:  8702406] 
[55] 
Sundvold H, Lien S. Identification of a novel peroxisome proliferator-activated receptor (PPAR) γ promoter in man and transactivation by the nuclear receptor RORalpha1. Biochem Biophys Res Commun  2001; 287(2): 383-90.
[http://dx.doi.org/10.1006/bbrc.2001.5602] [PMID:  11554739] 
[56] 
Celi FS, Shuldiner AR. The role of peroxisome proliferator-activated receptor gamma in diabetes and obesity. Curr Diab Rep  2002; 2(2): 179-85.
[http://dx.doi.org/10.1007/s11892-002-0078-2] [PMID:  12643137] 
[57] 
Kintscher U, Law RE. PPARgamma-mediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab  2005; 288(2): E287-91.
[http://dx.doi.org/10.1152/ajpendo.00440.2004] [PMID:  15637349] 
[58] 
Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS. PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev  2002; 16(1): 27-32.
[http://dx.doi.org/10.1101/gad.953802] [PMID:  11782442] 
[59] 
Chang TH. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Cancer Res  2000; 60: 1129-38.
[PMID:  10706135] 
[60] 
Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clin Invest  1997; 100(7): 1863-9.
[http://dx.doi.org/10.1172/JCI119715] [PMID:  9312188] 
[61] 
Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature  2001; 409(6818): 307-12.
[http://dx.doi.org/10.1038/35053000] [PMID:  11201732] 
[62] 
Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med  2001; 7(8): 947-53.
[http://dx.doi.org/10.1038/90992] [PMID:  11479628] 
[63] 
Dutchak PA, Katafuchi T, Bookout AL, et al. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell  2012; 148(3): 556-67.
[http://dx.doi.org/10.1016/j.cell.2011.11.062] [PMID:  22304921] 
[64] 
Ye JM, Dzamko N, Cleasby ME, et al. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia  2004; 47(7): 1306-13.
[http://dx.doi.org/10.1007/s00125-004-1436-1] [PMID:  15232684] 
[65] 
Koutnikova H, Cock TA, Watanabe M, et al. Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR γ hypomorphic mice. Proc Natl Acad Sci USA  2003; 100(24): 14457-62.
[http://dx.doi.org/10.1073/pnas.2336090100] [PMID:  14603033] 
[66] 
Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care  2002; 25(2): 376-80.
[http://dx.doi.org/10.2337/diacare.25.2.376] [PMID:  11815513] 
[67] 
Darwish KM, Salama I, Mostafa S, Gomaa MS, Helal MA. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists. Eur J Med Chem  2016; 109: 157-72.
[http://dx.doi.org/10.1016/j.ejmech.2015.12.049] [PMID:  26774923] 
[68] 
Taygerly JP, McGee LR, Rubenstein SM, et al. Discovery of INT131: a selective PPARγ modulator that enhances insulin sensitivity. Bioorg Med Chem  2013; 21(4): 979-92.
[http://dx.doi.org/10.1016/j.bmc.2012.11.058] [PMID:  23294830] 
[69] 
Furukawa A, Arita T, Fukuzaki T, et al. Synthesis and biological evaluation of novel (-)-Cercosporamide derivatives as potent selective PPARγ modulators. Eur J Med Chem  2012; 54: 522-33.
[http://dx.doi.org/10.1016/j.ejmech.2012.05.040] [PMID:  22727448] 
[70] 
Blöcher R, Lamers C, Wittmann SK, et al. N-benzylbenzamides: A novel merged scaffold for orally available dual soluble epoxide hydrolase/peroxisome proliferator-activated receptor γ modulators. J Med Chem  2016; 59(1): 61-81.
[http://dx.doi.org/10.1021/acs.jmedchem.5b01239] [PMID:  26595749] 
[71] 
Deka N, Uravane M, Anthony J, et al. Design and synthesis of non-TZD peroxisome proliferator-activated receptor γ (PPARγ) modulator. Med Chem Res  2014; 23(4): 2150-9.
[http://dx.doi.org/10.1007/s00044-013-0814-y] 
[72] 
Bajare S, Anthony J, Nair A, et al. Synthesis of N-(5-chloro-6-(quinolin-3-yloxy)pyridin-3-yl)benzenesulfonamide derivatives as non-TZD peroxisome proliferator-activated receptor γ (PPARγ) agonist. Eur J Med Chem  2012; 58: 355-60.
[http://dx.doi.org/10.1016/j.ejmech.2012.10.027] [PMID:  23142675] 
[73] 
Chou PS, Ho BL, Yang YH. Effects of pioglitazone on the incidence of dementia in patients with diabetes. J Diabetes Complications  2017; 31(6): 1053-7.
[http://dx.doi.org/10.1016/j.jdiacomp.2017.01.006] [PMID:  28254448] 
[74] 
Racke MK. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr Opin Neurol  2008; 21(Suppl. 1): S9-S18.
[http://dx.doi.org/10.1097/01.wco.0000313359.61176.15] [PMID:  18388801] 
[75] 
Hsu WJ, Wildburger NC, Haidacher SJ, et al. PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer’s disease. Exp Neurol  2017; 295: 1-17.
[http://dx.doi.org/10.1016/j.expneurol.2017.05.005] [PMID:  28522250] 
[76] 
de la Monte SM, Tong M, Schiano I, Didsbury J. Improved Brain Insulin/IGF Signaling and Reduced Neuroinflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer’s Disease. J Alzheimers Dis  2017; 55(2): 849-64.
[http://dx.doi.org/10.3233/JAD-160656] [PMID:  27802237] 
[77] 
Prathab Balaji S, Vijay Chand C, Justin A, Ramanathan M. Telmisartan mediates anti-inflammatory and not cognitive function through PPAR-γ agonism via SARM and MyD88 signaling. Pharmacol Biochem Behav  2015; 137: 60-8.
[http://dx.doi.org/10.1016/j.pbb.2015.08.007] [PMID:  26264163] 
[78] 
Wu G, Jiao Y, Wu J, et al. Rosiglitazone infusion therapy following minimally invasive surgery for ICH evacuation decreased perihematomal glutamate content as well as BBB permeability in rabbits. World Neurosurg 2017.
[79] 
Liu J, Wang LN. Peroxisome proliferator-activated receptor
gamma agonists for preventing recurrent stroke and other vascular
events in people with stroke or transient ischaemic attack Cochrane
Database Syst Rev  2017; 12CD010693
[http://dx.doi.org/10.1002/14651858.CD010693.pub4] 
[80] 
Yuan J, Ge H, Liu W, et al. M2 microglia promotes neurogenesis and oligodendrogenesis from neural stem/progenitor cells via the PPARγ signaling pathway. Oncotarget  2017; 8(12): 19855-65.
[http://dx.doi.org/10.18632/oncotarget.15774] [PMID:  28423639] 
[81] 
Rubin GL, Zhao Y, Kalus AM, Simpson ER. Peroxisome proliferator-activated receptor γ ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res  2000; 60(6): 1604-8.
[PMID:  10749129] 
[82] 
Hu J, Cao X, Pang D, et al. Tumor grade related expression of neuroglobin is negatively regulated by PPARγ and confers antioxidant activity in glioma progression. Redox Biol  2017; 12: 682-9.
[http://dx.doi.org/10.1016/j.redox.2017.03.023] [PMID:  28410531] 
[83] 
Copland JA, Marlow LA, Kurakata S, et al. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene  2006; 25(16): 2304-17.
[http://dx.doi.org/10.1038/sj.onc.1209267] [PMID:  16331265] 
[84] 
Ni J, Zhou LL, Ding L, et al. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway. Exp Cell Res  2017; 361(2): 246-56.
[http://dx.doi.org/10.1016/j.yexcr.2017.10.024] [PMID: 29080795] 
[85] 
Wang W, Liu F, Chen N. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists attenuate the profibrotic response induced by TGF-β1 in renal interstitial fibroblasts. Mediators Inflamm  2007; 2007: 62641.
[http://dx.doi.org/10.1155/2007/62641] [PMID:  18274641] 
[86] 
Zhang Y, Zhang X, Wang J, et al. Expression and Function of PPARs in Cancer Stem Cells. Curr Stem Cell Res Ther  2016; 11(3): 226-34.
[http://dx.doi.org/10.2174/1574888X10666150728122921] [PMID:  26216131] 
[87] 
Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care  2004; 27(4): 1015.
[http://dx.doi.org/10.2337/diacare.27.4.1015] [PMID:  15047668] 
[88] 
McTigue DM, Tripathi R, Wei P, Lash AT. The PPAR γ agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. Exp Neurol  2007; 205(2): 396-406.
[http://dx.doi.org/10.1016/j.expneurol.2007.02.009] [PMID:  17433295] 
[89] 
Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol  2005; 191(2): 331-6.
[http://dx.doi.org/10.1016/j.expneurol.2004.10.007] [PMID:  15649489] 
[90] 
Shibata N, Kawaguchi-Niida M, Yamamoto T, Toi S, Hirano A, Kobayashi M. Effects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis. Neuropathology  2008; 28(4): 387-98.
[http://dx.doi.org/10.1111/j.1440-1789.2008.00890.x] [PMID:  18312546] 
[91] 
Meng QQ, Liang XJ, Wang P, et al. Rosiglitazone enhances the proliferation of neural progenitor cells and inhibits inflammation response after spinal cord injury. Neurosci Lett  2011; 503(3): 191-5.
[http://dx.doi.org/10.1016/j.neulet.2011.08.033] [PMID:  21889575] 
[92] 
Li H, Zhang Q, Yang X, Wang L. PPAR-γ agonist rosiglitazone reduces autophagy and promotes functional recovery in experimental traumaticspinal cord injury. Neurosci Lett  2017; 650: 89-96.
[http://dx.doi.org/10.1016/j.neulet.2017.02.075] [PMID:  28433567] 
[93] 
Patel SP, Cox DH, Gollihue JL, et al. Pioglitazone treatment following spinal cord injury maintains acute mitochondrial integrity and increases chronic tissue sparing and functional recovery. Exp Neurol  2017; 293: 74-82.
[http://dx.doi.org/10.1016/j.expneurol.2017.03.021] [PMID:  28365473] 
[94] 
Jia H, Xu S, Liu Q, et al. Effect of pioglitazone on neuropathic pain and spinal expression of TLR-4 and cytokines. Exp Ther Med  2016; 12(4): 2644-50.
[http://dx.doi.org/10.3892/etm.2016.3643] [PMID:  27698768] 
[95] 
Benayoun L, Letuve S, Druilhe A, et al. Regulation of peroxisome proliferator-activated receptor γ expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling. Am J Respir Crit Care Med  2001; 164(8 Pt 1): 1487-94.
[http://dx.doi.org/10.1164/ajrccm.164.8.2101070] [PMID:  11704601] 
[96] 
Becker J, Delayre-Orthez C, Frossard N, Pons F. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol  2006; 20(5): 429-47.
[http://dx.doi.org/10.1111/j.1472-8206.2006.00425.x] [PMID:  16968414] 
[97] 
Belvisi MG, Hele DJ, Birrell MA. New anti-inflammatory therapies and targets for asthma and chronic obstructive pulmonary disease. Expert Opin Ther Targets  2004; 8(4): 265-85.
[http://dx.doi.org/10.1517/14728222.8.4.265] [PMID:  15268623] 
[98] 
Spears M, McSharry C, Thomson NC. Peroxisome proliferator-activated receptor-γ agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy  2006; 36(12): 1494-504.
[http://dx.doi.org/10.1111/j.1365-2222.2006.02604.x] [PMID:  17177672] 
[99] 
Birrell MA, Patel HJ, McCluskie K, et al. PPAR-γ agonists as therapy for diseases involving airway neutrophilia. Eur Respir J  2004; 24(1): 18-23.
[http://dx.doi.org/10.1183/09031936.04.00098303] [PMID:  15293600] 
[100] 
Ward JE, Fernandes DJ, Taylor CC, Bonacci JV, Quan L, Stewart AG. The PPARgamma ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation. Pulm Pharmacol Ther  2006; 19(1): 39-46.
[http://dx.doi.org/10.1016/j.pupt.2005.02.005] [PMID:  16286236] 
[101] 
Lee KS, Park SJ, Kim SR, et al. Modulation of airway remodeling and airway inflammation by peroxisome proliferator-activated receptor γ in a murine model of toluene diisocyanate-induced asthma. J Immunol  2006; 177(8): 5248-57.
[http://dx.doi.org/10.4049/jimmunol.177.8.5248] [PMID:  17015710] 
[102] 
Gu MX, Liu XC, Jiang L. [Effect of peroxisome proliferatoractivated
receptor-gamma on proliferation of airway smooth muscle
cells in mice with asthma] Zhongguo Dang Dai Er Ke Za Zhi. 2013; 15(7): 583-7. [Effect of peroxisome proliferator-activated receptor-
gamma on proliferation of airway smooth muscle cells in
mice with asthma]
[PMID:  23866284] 
[103] 
Maslanka T, Otrocka-Domagała I, Zuśka-Prot M, Gesek M. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma
agonist, reduces but does not prevent, the pulmonary CD4+ effector
T-cell response in a murine model of asthma 
[104] 
Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest  2000; 106(4): 523-31.
[http://dx.doi.org/10.1172/JCI10370] [PMID:  10953027] 
[105] 
Lim S, Lee KS, Lee JE, et al. Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis. Atherosclerosis  2015; 243(1): 107-19.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.08.037] [PMID:  26363808] 
[106] 
Marx N, Schönbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res  1998; 83(11): 1097-103.
[http://dx.doi.org/10.1161/01.RES.83.11.1097] [PMID:  9831704] 
[107] 
Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem  1999; 274(13): 9116-21.
[http://dx.doi.org/10.1074/jbc.274.13.9116] [PMID:  10085162] 
[108] 
Halabi CM, Beyer AM, de Lange WJ, et al. Interference with PPAR γ function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab  2008; 7(3): 215-26.
[http://dx.doi.org/10.1016/j.cmet.2007.12.008] [PMID:  18316027] 
[109] 
Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature  1999; 402(6764): 880-3.
[http://dx.doi.org/10.1038/47254] [PMID:  10622252] 
[110] 
Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension  2004; 43(5): 993-1002.
[http://dx.doi.org/10.1161/01.HYP.0000123072.34629.57] [PMID:  15007034] 
[111] 
Rani N, Bharti S, Bhatia J, Nag TC, Ray R, Arya DS. Chrysin, a PPAR-γ agonist improves myocardial injury in diabetic rats through inhibiting AGE-RAGE mediated oxidative stress and inflammation. Chem Biol Interact  2016; 250: 59-67.
[http://dx.doi.org/10.1016/j.cbi.2016.03.015] [PMID:  26972669] 
[112] 
Nolte RT, Wisely GB, Westin S, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature  1998; 395(6698): 137-43.
[http://dx.doi.org/10.1038/25931] [PMID:  9744270] 
[113] 
de Groot JC, Weidner C, Krausze J, et al. Structural characterization of amorfrutins bound to the peroxisome proliferator-activated receptor γ. J Med Chem  2013; 56(4): 1535-43.
[http://dx.doi.org/10.1021/jm3013272] [PMID:  23286787] 
[114] 
Guasch L, Sala E, Valls C, et al. Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity. J Comput Aided Mol Des  2011; 25(8): 717-28.
[http://dx.doi.org/10.1007/s10822-011-9446-9] [PMID: 21691811] 
[115] 
Liberato MV, Nascimento AS, Ayers SD, et al. Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonists. PLoS One  2012; 7(5)e36297
[http://dx.doi.org/10.1371/journal.pone.0036297] [PMID:  22649490] 
[116] 
Trombetta A, Maggiora M, Martinasso G, Cotogni P, Canuto RA, Muzio G. Arachidonic and docosahexaenoic acids reduce the growth of A549 human lung-tumor cells increasing lipid peroxidation and PPARs. Chem Biol Interact  2007; 165(3): 239-50.
[http://dx.doi.org/10.1016/j.cbi.2006.12.014] [PMID:  17275799] 
[117] 
Sun H, Berquin IM, Owens RT, O’Flaherty JT, Edwards IJ. Peroxisome proliferator-activated receptor γ-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells. Cancer Res  2008; 68(8): 2912-9.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-2305] [PMID:  18413760] 
[118] 
Yang ZH, Miyahara H, Iwasaki Y, Takeo J, Katayama M. Dietary supplementation with long-chain monounsaturated fatty acids attenuates obesity-related metabolic dysfunction and increases expression of PPAR γ in adipose tissue in type 2 diabetic KK-Ay mice. Nutr Metab (Lond)  2013; 10(1): 16.
[http://dx.doi.org/10.1186/1743-7075-10-16] [PMID:  23360495] 
[119] 
Heim M, Johnson J, Boess F, et al. Phytanic acid, a natural peroxisome proliferator-activated receptor (PPAR) agonist, regulates glucose metabolism in rat primary hepatocytes. FASEB J  2002; 16(7): 718-20.
[http://dx.doi.org/10.1096/fj.01-0816fje] [PMID:  11923221] 
[120] 
Tanaka-Yachi R, Takahashi-Muto C, Adachi K, et al. Promoting effect of α-tocopherol on beige adipocyte differentiation in 3T3-L1 cells and rat white adipose tissue. J Oleo Sci  2017; 66(2): 171-9.
[http://dx.doi.org/10.5650/jos.ess16137] [PMID:  28154348] 
[121] 
Campbell SE, Stone WL, Whaley SG, Qui M, Krishnan K. Gamma (gamma) tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma (gamma) expression in SW 480 human colon cancer cell lines. BMC Cancer  2003; 3(1): 25.
[http://dx.doi.org/10.1186/1471-2407-3-25] [PMID:  14521714] 
[122] 
Campbell SE, Musich PR, Whaley SG, et al. γ tocopherol upregulates the expression of 15-S-HETE and induces growth arrest through a PPAR γ-dependent mechanism in PC-3 human prostate cancer cells. Nutr Cancer  2009; 61(5): 649-62.
[http://dx.doi.org/10.1080/01635580902825654] [PMID:  19838939] 
[123] 
Salam NK, Huang TH, Kota BP, Kim MS, Li Y, Hibbs DE. Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study. Chem Biol Drug Des  2008; 71(1): 57-70.
[http://dx.doi.org/10.1111/j.1747-0285.2007.00606.x] [PMID:  18086153] 
[124] 
Nadal X, Del Río C, Casano S, et al. Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity. Br J Pharmacol  2017; 174(23): 4263-76.
[http://dx.doi.org/10.1111/bph.14019] [PMID:  28853159] 
[125] 
D’Aniello E, Fellous T, Iannotti FA, et al. Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach. Biochim Biophys Acta, Gen Subj  2019; 1863(3): 586-97.
[http://dx.doi.org/10.1016/j.bbagen.2019.01.002] [PMID:  30611848] 
[126] 
Dreier D, Latkolik S, Rycek L, et al. Linked magnolol dimer as a selective PPARγ agonist - Structure-based rational design, synthesis, and bioactivity evaluation. Sci Rep  2017; 7(1): 13002.
[http://dx.doi.org/10.1038/s41598-017-12628-5] [PMID:  29057944] 
[127] 
Dreier D, Resetar M, Temml V, et al. Magnolol dimer-derived fragments as PPARγ-selective probes. Org Biomol Chem  2018; 16(38): 7019-28.
[http://dx.doi.org/10.1039/C8OB01745J] [PMID:  30232493] 
[128] 
Zurlo D, Ziccardi P, Votino C, et al. The antiproliferative and proapoptotic effects of cladosporols A and B are related to their different binding mode as PPARγ ligands. Biochem Pharmacol  2016; 108: 22-35.
[http://dx.doi.org/10.1016/j.bcp.2016.03.007] [PMID:  26995279] 
[129] 
Weidner C, Rousseau M, Micikas RJ, et al. Amorfrutin C induces apoptosis and inhibits proliferation in colon cancer cells through targeting mitochondria. J Nat Prod  2016; 79(1): 2-12.
[http://dx.doi.org/10.1021/acs.jnatprod.5b00072] [PMID:  26731300] 
[130] 
Georgiadis I, Karatzas T, Korou LM, et al. Evaluation of Chios mastic gum on lipid and glucose metabolism in diabetic mice. J Med Food  2014; 17(3): 393-9.
[http://dx.doi.org/10.1089/jmf.2013.0069] [PMID:  24404977] 
[131] 
Zou G, Gao Z, Wang J, et al. Deoxyelephantopin inhibits cancer cell proliferation and functions as a selective partial agonist against PPARgamma. Biochem Pharmacol  2008; 75(6): 1381-92.
[http://dx.doi.org/10.1016/j.bcp.2007.11.021] [PMID:  18164690] 
[132] 
Xu ME, Xiao SZ, Sun YH, Ou-Yang Y, Zheng XX. Effects of astragaloside IV on pathogenesis of metabolic syndrome in vitro. Acta Pharmacol Sin  2006; 27(2): 229-36.
[http://dx.doi.org/10.1111/j.1745-7254.2006.00243.x] [PMID:  16412274] 
[133] 
Wang X, Wang Y, Hu JP, et al. Astragaloside IV, a natural PPARγ agonist, reduces Aβ production in Alzheimer’s disease through inhibition of BACE1. Mol Neurobiol  2017; 54(4): 2939-49.
[http://dx.doi.org/10.1007/s12035-016-9874-6] [PMID:  27023226] 
[134] 
Sun B, Rui R, Pan H, Zhang L, Wang X. Effect of Combined Use of Astragaloside IV (AsIV) and Atorvastatin (AV) on Expression of PPAR-γ and Inflammation-Associated Cytokines in Atherosclerosis Rats. Med Sci Monit  2018; 24: 6229-36.
[http://dx.doi.org/10.12659/MSM.908480] [PMID:  30190450] 
[135] 
Feng L, Luo H, Xu Z, et al. Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-γ and PPAR-α agonists on carbohydrate and lipid metabolism in db/db and diet-induced obese mice. Diabetologia  2016; 59(6): 1276-86.
[http://dx.doi.org/10.1007/s00125-016-3912-9] [PMID:  26983922] 
[136] 
Qian J, Xie F, Shi Y, et al. Pharmacokinetic and metabolism studies of bavachinin through ultra-high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Biomed Chromatogr  2018; 32(10)e4293
[http://dx.doi.org/10.1002/bmc.4293] [PMID:  29782651] 
[137] 
Du G, Zhao Y, Feng L, et al. Design, Synthesis, and Structure-Activity Relationships of Bavachinin Analogues as Peroxisome Proliferator-Activated Receptor γ Agonists. ChemMedChem  2017; 12(2): 183-93.
[http://dx.doi.org/10.1002/cmdc.201600554] [PMID:  27914122] 
Rights & Permissions Print Cite
Article Metrics
60
4
1
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1389450120666190527115538	Print ISSN 1389-4501
Publisher Name Bentham Science Publisher	Online ISSN 1873-5592
Current Drug Targets

PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Related Articles

Abstract
